Oklo's Groves reactor just cleared its final safety hurdle. First criticality is days away. The stock is down 73% from its all-time high. Here is the full picture — what Oklo does, what the financials say, why it collapsed, and whether the risk-reward makes sense right now.
Oklo Inc. (NYSE: OKLO) is at a critical point right now. And that word — critical — carries two meanings that could not be more fitting. In nuclear physics, criticality is the moment a reactor achieves a controlled, self-sustaining chain reaction. In financial terms, it is the moment a company stands at a fork in the road — one path toward vindication, the other toward a longer, harder fall. Oklo is facing both simultaneously.
The Groves Isotope Test Reactor in Lockhart, Texas just cleared its final safety hurdle on July 1, 2026. First criticality is being targeted for July 2026. A competitor in the same government programme has already beaten Oklo to the milestone. The stock is down 73% from its all-time high. The DOE just approved the final safety analysis. The company has $2.5 billion in cash and zero revenue. Every signal is pointing in a different direction — and investors are being asked to decide what to make of it.
This is the OKLO story in full: what it does, the latest milestones, what the financials actually say, why the stock collapsed, and whether the risk-reward makes sense right now.
What Does Oklo Actually Do?
Oklo develops small modular nuclear reactors (SMRs), specifically fast-fission reactors it calls Aurora Powerhouses. Unlike conventional nuclear plants that use water to cool the reactor core, Oklo’s design uses liquid sodium — a more efficient heat transfer medium that allows the reactor to run on both fresh uranium fuel and recycled used nuclear fuel. The Aurora Powerhouse is designed to produce between 15 and 75 megawatts of electricity, making it far smaller and faster to build than a traditional gigawatt-scale nuclear plant.
The pitch to customers — large data centre operators, industrial companies, and the US military — is simple: a dedicated, always-on power supply that does not depend on the grid, uses no fossil fuels, and can be sited close to the customer’s load. Oklo does not sell the reactor. It owns and operates the reactor and sells the electricity directly under long-term power purchase agreements, a model borrowed from early-stage renewables that generates recurring revenue rather than a one-time equipment sale.
Beyond power, Oklo operates a second business through its subsidiary Atomic Alchemy: the production of radioisotopes used in cancer diagnosis and treatment, advanced manufacturing, scientific research, space exploration, and national security. The customer pipeline now stands at 14 gigawatts, anchored by Meta, NVIDIA, Equinix, Switch, and the US Air Force.
The Groves Reactor: What Just Happened
On July 1, 2026 — one day before this article — the US Department of Energy approved the Documented Safety Analysis (DSA) for Oklo’s Groves Isotope Test Reactor in Lockhart, Texas. This is the final safety document required before Oklo can move into the last pre-startup phase: a DOE readiness review, fuel loading, and then first criticality.
The timing is tight — and there is a wrinkle. Reports emerged that Oklo altered the Groves reactor configuration ahead of the criticality push, a detail the Yahoo Finance article linked by readers flagged. Separately, competitor Antares Nuclear has already achieved criticality under the same DOE Reactor Pilot Program, meaning Oklo will not be first to that milestone within the programme. Neither development is fatal to the Oklo thesis, but both are worth noting: the alteration suggests the path to July criticality is not entirely straightforward, and the Antares milestone removes the “first to criticality” bragging right Oklo investors had been anticipating.
What has not changed: Groves is not Oklo’s main commercial product — it is a test and data-collection platform designed to generate operating experience before Atomic Alchemy scales to production-level isotope reactors. The commercial isotope revenue narrative runs separately through the Idaho Radiochemistry Laboratory, where the NRC already issued Atomic Alchemy a materials licence in March 2026 to handle and distribute select isotopes. CEO Jacob DeWitte has said the Idaho facility “is expected to make first revenue this year” — a statement that does not depend on Groves going critical on schedule.
Six Months of Milestones
Since the start of 2026, Oklo has announced a 1.2-gigawatt power campus agreement with Meta Platforms in Ohio, submitted interconnection applications for that campus, received a Notice of Intent to Award from the US Air Force for a deployment at Eielson Air Force Base in Alaska, broke ground on its first commercial Aurora Powerhouse at Idaho National Laboratory, signed a letter of intent with Centrus Energy to purchase nuclear fuel — reducing dependence on Russian-sourced uranium — and partnered with Standard Nuclear on fuel recycling and manufacturing.
On May 6, 2026, the NRC approved Oklo’s Principal Design Criteria for the Aurora Powerhouse on an accelerated schedule — a regulatory de-risking event analysts noted the market underweighted. None of this has produced a dollar of commercial revenue. But the regulatory and customer momentum is real and accelerating.
The Financials: Pre-Revenue, Not Pre-Progress
Oklo is a pre-revenue company. In Q1 2026, the company reported a net loss of $33.1 million and an operating loss of $51.2 million, driven by headcount growth, engineering spend, reactor licensing costs, and stock-based compensation. Revenue was zero. Loss per share was $0.19, fractionally worse than the consensus estimate of $0.18.
| Metric | Q1 2026 | Q1 2025 | Change YoY |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net loss | -$33.1M | -$9.8M | Widened 3× |
| Operating loss | -$51.2M | — | — |
| Loss per share | -$0.19 | -$0.07 | Worse |
| Operating cash burn | -$17.9M | -$12M | +49% YoY |
| Cash & investments | $2.5B | — | Post $1.2B raise |
| Full-year cash burn guide | $80M–$100M operating + $350M–$450M capex | ||
Why Did the Stock Drop 73% From Its High?
Three things happened simultaneously, and none of them were specific to Oklo’s execution on the ground.
| Factor | What Happened | Impact on Stock |
|---|---|---|
| Speculative unwind | Nuclear mania of 2025 reversed as risk appetite faded across the market | Entire sector sold off from extreme valuations |
| Dilution | $1.2B ATM raise in Q1 2026, followed by a new $1B offering filing | Existing shareholders diluted; stock fell further post-announcement |
| Widening losses | Q1 net loss hit $33.1M vs $9.8M a year ago; zero revenue | Investors expecting near-term results exited the trade |
In 2025, a perfect storm of pro-nuclear policy from the Trump administration, hyperscaler power demand announcements, and retail momentum pushed every nuclear stock to extreme valuations. Oklo peaked at $193.84 in October 2025. At that level, the stock was pricing in years of perfect execution and unlimited optimism. When sentiment shifted — as it inevitably does with speculative pre-revenue stocks — there was nothing fundamental to arrest the decline.
Is Oklo a Good Stock to Buy Right Now?
The honest answer depends entirely on whether you can hold through 2027 or 2028 without a single dollar of commercial revenue. Seventeen of 18 Wall Street analysts covering the stock rate it a Buy or equivalent, with a consensus price target of around $90 — roughly 70% above the current price. Tigress Financial carries a $130 target; William Blair has an Outperform rating.
| Bull Case | Bear Case |
|---|---|
| 14 GW customer pipeline — Meta, NVIDIA, Equinix, US Air Force | Zero commercial revenue — none expected before 2028 |
| $2.5B cash removes near-term dilution risk entirely | Aurora-INL is first-of-kind: no comparable build cost data |
| NRC and DOE regulatory environment most favourable in decades | Customer pipeline largely non-binding letters of intent |
| Groves criticality validates fast-fission technology | $9B market cap for a pre-revenue company is speculative by definition |
| Own-and-operate model creates recurring revenue once live | Continued equity raises likely as reactor construction scales |
| First-mover advantage in commercial fast-spectrum reactors | A single regulatory delay could reprice the stock sharply lower |
The stock today is a different proposition from October 2025. At $52, investors are not paying peak-nuclear-mania prices. But they are still paying a roughly $9 billion market cap for a company with zero revenue and a first-of-kind reactor design that has never operated commercially. That is speculative by definition.
OKLO is not an investment in a business right now. It is a bet on a sequence of events — Groves goes critical, Aurora-INL achieves first power around 2027, the NRC continues modernising licensing, and hyperscaler customers convert non-binding agreements into firm contracts. Every link in that chain has to hold.
The DSA approval of July 1 matters more as an investor signal than as a business event. As analyst commentary noted after the announcement, investor sentiment around Oklo tends to respond to regulatory momentum — and the DOE just delivered the most meaningful regulatory milestone Oklo has ever received outside a national laboratory. The question is whether the stock can sustain momentum through the remaining steps: DOE readiness review, fuel loading, and criticality itself.
If Groves goes critical in July, expect a meaningful sentiment bounce — this is the kind of proof-of-concept moment that can re-rate a speculative stock. If the milestone slips — whether due to the reported reactor alterations, procurement gaps, or timeline compression — expect more pressure at a stock that has already given back 73% from its peak.
For traders, OKLO is a milestone-driven stock with several near-term catalysts. For long-term investors, the question is simpler: can you hold through 2028 for the first dollar of commercial revenue? At $52, the setup is more interesting than it was at $193. But the risks are real, and they are not small.
What to Watch Next
Three catalysts will define the OKLO story over the next six months. First, Groves criticality in July 2026 — the reactor either goes critical or it does not, and the stock will react accordingly. Second, Q2 2026 earnings in August, where management will update the Aurora-INL construction timeline and cash position. Third, whether the Meta interconnection application in Ohio moves toward a binding power purchase agreement — the point at which a 1.2 GW customer relationship becomes contractual revenue.
For a broader read on where the global economy stands heading into Q3 — including AI infrastructure investment and energy security dynamics that underpin the nuclear investment thesis — see our State of the Global Economy Q3 2026.
This article is for informational and educational purposes only and does not constitute financial or investment advice. OKLO is a speculative, pre-revenue stock. Trading speculative stocks involves significant risk of loss. Data sourced from Oklo Q1 2026 SEC filings, Oklo investor relations, BusinessWire, Yahoo Finance, TIKR, and Investing.com. Accurate as of July 2, 2026.